Financial reports
NT 10-K
Notice of late annual filing
2 Apr 24
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
10-Q
2023 Q2
Quarterly report
15 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
16 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
12 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-K/A
2021 FY
Annual report (amended)
16 Dec 22
Current reports
8-K
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
19 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Mar 24
8-K
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio
22 Jan 24
8-K/A
Entry into a Material Definitive Agreement
29 Dec 23
8-K
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023
29 Dec 23
8-K
Departure of Directors or Certain Officers
28 Nov 23
8-K
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
22 Nov 23
8-K
COSMOS HEALTH CEO Issues Letter to Shareholders
10 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Oct 23
8-K
Departure of Directors or Certain Officers
22 Sep 23
Registration and prospectus
424B3
Prospectus supplement
7 Mar 24
424B3
Prospectus supplement
29 Feb 24
424B3
Prospectus supplement
15 Feb 24
S-3
Shelf registration
29 Jan 24
424B3
Prospectus supplement
31 Aug 23
S-3
Shelf registration
18 Aug 23
D
$5.25 mm in equity / options, sold $5.25 mm, 3 investors
27 Jul 23
424B5
Prospectus supplement for primary offering
21 Jul 23
424B5
Prospectus supplement for primary offering
21 Jul 23
424B3
Prospectus supplement
27 Jan 23
Proxies
DEF 14A
Definitive proxy
5 Sep 23
PRE 14A
Preliminary proxy
23 Aug 23
DEF 14A
Definitive proxy
20 Oct 22
PRE 14A
Preliminary proxy
23 Sep 22
DEF 14C
Information statement
1 Mar 22
PRE 14C
Preliminary information
17 Feb 22
PRE 14C
Preliminary information
22 Dec 21
DEF 14C
Information statement
13 Sep 21
PRE 14C
Preliminary information
2 Sep 21
DEF 14C
Information statement
18 Sep 17
Other
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
5 Feb 24
EFFECT
Notice of effectiveness
1 Sep 23
CORRESP
Correspondence with SEC
29 Aug 23
UPLOAD
Letter from SEC
25 Aug 23
EFFECT
Notice of effectiveness
30 Jan 23
CORRESP
Correspondence with SEC
25 Jan 23
UPLOAD
Letter from SEC
24 Jan 23
UPLOAD
Letter from SEC
4 Jan 23
Ownership